Overview of Strategies to Improve Therapy against Tumors Using Natural Killer Cell

被引:13
|
作者
Yang, Chaopin [1 ,2 ]
Li, Yue [1 ,2 ]
Yang, Yaozhang [1 ,2 ]
Chen, Zhiyi [1 ,2 ]
机构
[1] Guangzhou Med Univ, Dept Ultrasound Med, Lab Ultrasound Mol Imaging, Affiliated Hosp 3, Guangzhou 510150, Peoples R China
[2] Guangzhou Med Univ, Liwan Hosp, Expt Ctr, Affiliated Hosp 3, Guangzhou 510176, Peoples R China
基金
中国国家自然科学基金;
关键词
NK-92; CELLS; NK CELLS; CYTOTOXICITY RECEPTORS; CHEMOKINE RECEPTORS; CANCER; IMMUNOTHERAPY; ANTITUMOR; CHECKPOINT; IMMUNITY; TIGIT;
D O I
10.1155/2020/8459496
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
NK cells are lymphocytes with antitumor properties and can directly lyse tumor cells in a non-MHC-restricted manner. However, the tumor microenvironment affects the immune function of NK cells, which leads to immune evasion. This may be related to the pathogenesis of some diseases. Therefore, great efforts have been made to improve the immunotherapy effect of natural killer cells. NK cells from different sources can meet different clinical needs, in order to minimize the inhibition of NK cells and maximize the response potential of NK cells, for example, modification of NK cells can increase the number of NK cells in tumor target area, change the direction of NK cells, and improve their targeting ability to malignant cells. Checkpoint blocking is also a promising strategy for NK cells to kill tumor cells. Combination therapy is another strategy for improving antitumor ability, especially in combination with oncolytic viruses and nanomaterials. In this paper, the mechanisms affecting the activity of NK cells were reviewed, and the therapeutic potential of different basic NK cell strategies in tumor therapy was focused on. The main strategies for improving the immune function of NK cells were described, and some new strategies were proposed.
引用
收藏
页数:16
相关论文
共 50 条
  • [1] Strategies to Augment Natural Killer (NK) Cell Activity against Solid Tumors
    Chen, Ziqing
    Yang, Ying
    Liu, Lisa L.
    Lundqvist, Andreas
    CANCERS, 2019, 11 (07)
  • [2] Natural Killer Cell Therapy Against Retinoblastoma
    Jo, D. H.
    Kim, J. H.
    Jun, H. O.
    Cho, C. S.
    Bak, E.
    Lee, S.
    Yoon, S. R.
    Park, Y. J.
    Park, K. D.
    Choi, I.
    Kim, J. H.
    PEDIATRIC BLOOD & CANCER, 2017, 64 : S129 - S129
  • [3] Evaluating natural killer cell cytotoxicity against solid tumors using a microfluidic model
    Ayuso, Jose M.
    Truttschel, Regan
    Gong, Max M.
    Humayun, Mouhita
    Virumbrales-Munoz, Maria
    Vitek, Ross
    Felder, Mildred
    Gillies, Stephen D.
    Sondel, Paul
    Wisinski, Kari B.
    Patankar, Manish
    Beebe, David J.
    Skala, Melissa C.
    ONCOIMMUNOLOGY, 2019, 8 (03):
  • [4] Natural Killer Cell Therapy: A New Treatment Paradigm for Solid Tumors
    Oh, Sooyeon
    Lee, Joo-Ho
    Kwack, KyuBum
    Choi, Sang-Woon
    CANCERS, 2019, 11 (10)
  • [5] Natural Killer Cells for Therapy of Neural Tumors
    Laureano, Alvaro M.
    Silla, Lucia M. R.
    Huls, Helen
    Liadi, Ivan
    Khatua, Soumen
    Lee, Dean A.
    Varadarajan, Navin
    Champlin, Richard E.
    Gopalakrishnan, Vidya
    Cooper, Laurence J.
    MOLECULAR THERAPY, 2012, 20 : S66 - S67
  • [6] The natural killer cell immunotherapy platform: An overview of the landscape of clinical trials in liquid and solid tumors
    Piccinelli, Sara
    Romee, Rizwan
    Shapiro, Roman M.
    SEMINARS IN HEMATOLOGY, 2023, 60 (01) : 42 - 51
  • [7] Adoptive cell therapy using engineered natural killer cells
    Katayoun Rezvani
    Bone Marrow Transplantation, 2019, 54 : 785 - 788
  • [8] Adoptive cell therapy using engineered natural killer cells
    Rezvani, Katayoun
    BONE MARROW TRANSPLANTATION, 2019, 54 (Suppl 2) : 785 - 788
  • [9] Natural Killer Cell Mechanosensing in Solid Tumors
    Lightsey, Suzanne
    Sharma, Blanka
    BIOENGINEERING-BASEL, 2024, 11 (04):
  • [10] Allogeneic natural killer cell therapy
    Berrien-Elliott, Melissa M.
    Jacobs, Miriam T.
    Fehniger, Todd A.
    BLOOD, 2023, 141 (08) : 856 - 868